Q-omics provides the consensus-scored DLGAP1-AS1 profile across patient tissues and cancer cell-line models. DLGAP1-AS1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DLGAP1-AS1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, DLGAP1-AS1 RNA expression shows 15,997 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, KICH, and KIRP as cancer lineages where DLGAP1-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLGAP1-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLGAP1-AS1 survival associations across molecular data types. DLGAP1-AS1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLGAP1-AS1 RNA expression–survival associations across cancer types. High DLGAP1-AS1 expression shows unfavorable associations in KIRC, ACC, LGG, UVM and LUAD, but favorable associations in BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for DLGAP1-AS1 RNA expression.
This table summarizes DLGAP1-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for DLGAP1-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLGAP1-AS1 shows lower tumor expression in KICH and KIRC and higher tumor expression in LIHC, HNSC, COAD and BRCA. The KICH box plot shows higher DLGAP1-AS1 RNA expression in normal versus tumor tissue (log2 FC = −2.198, t-test p < 0.001).
This table shows molecular features associated with DLGAP1-AS1 in patient tissues and cancer cell lines. In patient samples, DLGAP1-AS1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, DLGAP1-AS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY.
